New Pharmaceutical Industry Report Examines HIV/AIDS Medications
The market for HIV/AIDS drugs is "expected" to rise from the current $5 billion in sales to more than $13 billion by 2007, according to a report released last week by Griffin Securities Inc., a global investment banking, financial advisory and brokerage firm. The report states that although these drugs on average prolong the life of HIV-positive individuals by 1.8 years, the HIV/AIDS market is "immature," and "new drugs and adjunct therapies with novel mechanisms of action or unique resistance profiles are sorely needed." According to the report, there are currently 18 HIV/AIDS drugs on the market, while 100 new drug applications have been submitted to the FDA. Noting that there are three types of HIV/AIDS drugs on the market -- nucleoside reverse transcriptase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors -- the report examines which pharmaceutical companies and which drug makers fare best in sales of each class of drugs and which companies have the most promising pipeline drugs. The report also looks at other treatment candidates, including entry inhibitors, immune-based therapies and vaccines ("HIV/AIDS Industry Report: Major Developments in the Treatment of AIDS," July 2001). To request a free copy of the report, go to http://www.griffinsecurities.com/freeresearch.asp.This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.